Latest Breaking News On - Advanced solid tumors - Page 1 : comparemela.com

Pacylex Publishes Phase 1 Safety and Efficacy of Zelenirstat in Cancer Patients in the Journal Investigational New Drugs

Pacylex Publishes Phase 1 Safety and Efficacy of Zelenirstat in Cancer Patients in the Journal Investigational New Drugs
torontotelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from torontotelegraph.com Daily Mail and Mail on Sunday newspapers.

Reportable incPacylex pharmaceuticalsCure cancer foundationUs department of defensePacylex pharmaceuticals incCanada juneInvestigational newFirst in human phasei trialDaily oral zelenirstatN myristoyltransferase inhibitorAdvanced solid tumorsRefractoryb cell lymphomasHodgkin lymphomaOrphan drug designationFast track designation

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO Annual Meeting

Sarah Cannon Research Institute to Present Latest Cancer Research Insights at 2024 ASCO Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJeremy pantinSusanna ulahannanGerald falchookAbdul naqashTim larsonDavid spigelManish patelJoyce oshaughnessyMeredith mckeanTrastuzumab emtansineJessica thomes pepinAntonella cammarotaIshwaria subbiahDurvalumab olaparib

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting

NKGen Biotech, Inc. announced an online publication, titled ?Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity.

United statesMccormick placeNkgen biotech incMccormick place convention centerAmerican society of clinical oncologyInterim analysisPhasei studyAdvanced solid tumorsClinical oncologyAnnual meeting

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeKevin gardnerDenise chuaChris calabreseExchange commissionAmerican society of clinical oncologyNkgen biotech incGlobe newswire nkgen biotech incLifesci advisorsSecurities exchangeMccormick place convention centerCorporate communicationsBiotech publishes phaseAnalysis resultsAdvanced solid tumors

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

EQS-News: MorphoSys AG / Key word: Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting.

United statesKaitlyn nealyThomas biegiJulia neugebauerAmerican society of clinical oncologyCorporate affairsLymphoma societyConstellation pharmaceuticals incSys to present new phaseOral presentationClinical oncologyEfficacy dataCombination with ruxolitinibPatients withAdvanced solid tumorsVice president